Rilzabrutinib (1) – Wayrilz®
Immune thrombocytopenia (ITP), refractory
Characteristics
| Start date | 01.10.2026 |
|---|---|
| Resolution | 01.04.2027 – active procedure |
| INN | Rilzabrutinib |
| Brand name | Wayrilz® |
| Pharm. company | Sanofi-Aventis Deutschland GmbH |
| G-BA Procedure ID | D-1383 |
| Therapeutic area | Hematopoietic diseases Orphan |
| Reason for procedure | Initial assessment |
Associated procedures
| Rilzabrutinib (1) | Wayrilz® | Sanofi-Aventis Deutschland GmbH | Immune thrombocytopenia (ITP), refractory | n.d. | active procedure Orphan |
<< List of all resolutions